These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 38783146)

  • 1. The relationship between SGLT2 and systemic blood pressure regulation.
    Ahwin P; Martinez D
    Hypertens Res; 2024 Aug; 47(8):2094-2103. PubMed ID: 38783146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis.
    Kimura G
    J Am Soc Hypertens; 2016 Mar; 10(3):271-8. PubMed ID: 26874564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.
    Layton AT; Vallon V
    Am J Physiol Renal Physiol; 2018 May; 314(5):F969-F984. PubMed ID: 29361669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
    Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
    BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
    Sanidas EA; Papadopoulos DP; Hatziagelaki E; Grassos C; Velliou M; Barbetseas J
    Am J Hypertens; 2020 Mar; 33(3):207-213. PubMed ID: 31541572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors.
    Kugathasan L; Dubrofsky L; Advani A; Cherney DZI
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):15-34. PubMed ID: 36524239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System.
    Ansary TM; Nakano D; Nishiyama A
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
    Vallon V
    Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na
    Kravtsova O; Bohovyk R; Levchenko V; Palygin O; Klemens CA; Rieg T; Staruschenko A
    Am J Physiol Renal Physiol; 2022 Jun; 322(6):F692-F707. PubMed ID: 35466690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
    Lovshin JA; Gilbert RE
    Curr Hypertens Rep; 2015 Jun; 17(6):551. PubMed ID: 25893475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and Mechanisms of Hypertension.
    Briasoulis A; Al Dhaybi O; Bakris GL
    Curr Cardiol Rep; 2018 Jan; 20(1):1. PubMed ID: 29349558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.